Deciphera Pharmaceuticals, Inc. (DCPH)
(Delayed Data from NSDQ)
$23.59 USD
+0.67 (2.92%)
Updated May 3, 2019 04:00 PM ET
After-Market: $23.47 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DCPH 23.59 +0.67(2.92%)
Will DCPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DCPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DCPH
Is Inspire Small/Mid Cap ETF (ISMD) a Strong ETF Right Now?
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
DCPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates